Testifying methylomics blood test for new kidney cancer monitoring
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed kidney cancer
- You have not received any cancer treatment yet
- You plan to have curative (radical) surgery as your treatment
- Your usual day-to-day ability is good (ECOG score 0–1)
- You can follow the study’s follow-up visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test can help doctors tell if a kidney mass is cancer before surgery. It aims to improve how kidney masses are classified and guide treatment decisions.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
This study uses an at-home-style urine test (urine “omics,” meaning detailed lab information) to help predict how well immunotherapy may work for advanced kidney cancer. If you join, your urine results may help doctors tailor treatment choices and better understand who benefits most.
This study tests whether a simple blood test that tracks tumor DNA (called ctDNA) can help predict how well immunotherapy will work for people with non-clear cell kidney cancer. If you are about to start immunotherapy for advanced disease, this study could help your doctor better understand your treatment response.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.